FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Flynn Peter D						2. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [FATE]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last)	(Fi	rst) ((Midd	lle)		3. Date of Earliest Transaction (Month/Day/Year) 05/01/2014								X Officer (give title below)				(specify	
C/O FAT	ΓE THERA	PEUTICS, INC.														See re	marks		
3535 GENERAL ATOMICS COURT, SUITE 200					4. If a	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)														X	Form	n filed by One	Reporting Per	son	
SAN DIE	SAN DIEGO CA 92121											Form filed by More than One Reporting Person							
(City)	(Si	tate) (
		Tab	le I	- Non-Deri	/ative	Sec	urit	ies /	Acquire	ed, C	Disposed	of, or E	3enefi	cially	Own	ed			
Date			2. Transaction Date (Month/Day/Ye	ar) if a	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			and 5) Secu Ben Own		rities ficially ed	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price		Repo		(Instr. 4)	(Instr. 4)	
Common	Stock			05/01/201	4				M		6,925	A	\$1	.63		13,656	D		
Common Stock				05/01/201	4				M		1,100	A	\$1	.63		14,756	D		
Common Stock 05/01/2			05/01/201	4	i l			M		422	A	\$1	.37		15,178 D				
Common Stock 05/01/2014			4			S ⁽¹⁾		9,793	D	\$7.06	662(2)(3)		5,385	D					
		Ta	able	e II - Deriva (e.g., p							posed of , converti				vned	l			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe	Deemed cution Date, ny	4. Transac Code (I 8)		5. Number		6. Date Exel Expiration I (Month/Day /e es d		ate	1		Secu (Inst	vative irity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownership Form: y Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amou or Numb of Share	er					
Stock Option (right to buy)	\$1.63	05/01/2014			M			6,925	(4)		02/08/2022	Common Stock	6,92	5	5)	30,816	D		
Stock Option (right to buy)	\$1.63	05/01/2014			M			1,100	(6)		02/08/2022	Common Stock	1,10	0	5)	25,300	D		
Stock Option (right to buy)	\$1.37	05/01/2014			M			422	(7)		07/23/2022	Common Stock	422	2	5)	19,872	D		

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2013.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.00 to \$7.19, inclusive.
- 3. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- 4. The shares subject to this option shall vest and become exercisable at the rate of 1/4th of the shares on May 30, 2012 and 1/48th of the shares each month thereafter such that this option is fully exercisable on May 30, 2015. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.
- 5. Not applicable.

- 6. The shares subject to this option shall vest and become exercisable in 24 equal monthly installments beginning on the date one month after the completion of the Issuer's initial public offering. This option is subject to accelerated vesting upon a change of control of the Issuer after the completion of the Issuer's initial public offering.
- 7. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 3, 2012 such that this option is fully exercisable on July 3, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.

Remarks:

Senior Vice President, Early Program Development

/s/ Cindy R. Tahl, as Attorneyin-Fact 05/05/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.